Pharma Pulse 2/26/25: From Oral Medication to Liquid, FDA Accepts NDA for Epioxa Eye Therapy & more

From Oral Medication to Liquid

Aspargo Labs uses a proprietary technology platform to reformulate oral medication to liquid doses. CEO and chairman Michael Demurjian spoke with Pharmaceutical Executive about the development of the platform and the benefits of its uses.

FDA Accepts NDA for Epioxa Eye Therapy

After receiving the Day 74 letter, which outlines the FDA’s initial assessment of the application, the agency accepted Epioxa for review for efficacy and safety and plans to complete the process by October 20, 2025 under the Prescription Drug User Fee Act (PDUFA).

CVS Health Ordered to Comply With FTC Demand for Records

A federal judge in Washington ordered CVS Health Corp. to comply with a document request from the US Federal Trade Commission, a win for the antitrust and consumer protection agency in its long-running conflict with drug benefits middlemen.

ReAlta Life Sciences Announces Appointment of Biotechnology Leader Andrew Miller, PhD, to Board of Directors

Dr. Miller brings extensive experience in biotechnology leadership, drug development, and corporate strategy, having previously founded Karuna Therapeutics, a biopharmaceutical company developing treatments for psychiatric and neurological conditions. He most recently served as President of Research and Development at Karuna until its $14 billion acquisition by Bristol Myers Squibb in 2024.

RazorMetrics on LinkedIn

Don't miss this interview! RazorMetrics' CEO, Tom Dorsett talks to Pharmaceutical Commerce Magazine about polypharmacy, an overlooked driver of unnecessary spending and adverse health outcomes.

#razormetrics #biosimilars #pharmaceuticalcommerce https://hubs.ly/Q0382T760

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs